MIRM - Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
- Albireo developed Odevixibat- a product as a pipeline - as a life saving therapy for multiple ultra rare pediatric liver disease indications.
- The market potential is in the billions and well reachable with the announced positive Phase 3 results and PDUFA date set on 21 July.
- Launch of Odevixibat and sale of the Priority Review Voucher to strengthen the cash position is planned in the second half of 2021.
- Albireo is in the leadership role within the market and can successfully differentiate itself from competition to achieve a high penetration in the limited market.
- The share has the chance to become a ten-bagger with acceptable downside from current levels.
For further details see:
Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat